Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS)

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Baranova, Ancha ^a,b   Tran, Thuy Phuong ^a,b   Afendy, Arian ^a,c   Wang, Lei ^a,b   Shamsaddini, Amirhossein ^a,b   Mehta, Rohini ^a,b   Chandhoke, Vikas ^b   Birerdinc, Aybike ^a,b   Younossi, Zobair M ^a,c  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Apoptosis; LDLR; M30; NAFLD; Ninein; PCOS; Resistin

Indexed keywords

ADIPOCYTOKINE; ANDROGEN; BIOLOGICAL MARKER; GLYCOGEN SYNTHASE KINASE 3 BETA INTERACTION PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; RESISTIN; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GLYCOGEN SYNTHASE KINASE 3 BETA INTERACTION PROTEIN GENE; HUMAN; HUMAN TISSUE; HYPERANDROGENISM; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LOW DENSITY LIPOPROTEIN RECEPTOR GENE; MARKER GENE; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME;

ADIPOKINES; ADIPOSE TISSUE; ADULT; ANDROGENS; APOPTOSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; KERATIN-18; MIDDLE AGED; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; POLYCYSTIC OVARY SYNDROME; RECEPTORS, LDL; REGRESSION ANALYSIS; RESISTIN; RNA, MESSENGER;

EID: 84878351873     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-133     Document Type: Article

References (35)

1. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006, 12:324-332.
2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41-47. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.
3. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in over-weight and obese women. Arch Intern Med 2006, 166:2081-2086. 10.1001/archinte.166.19.2081, 17060537.
4. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010, 8:41. 10.1186/1741-7015-8-41, 2909929, 20591140.
5. Bjorntorp P. Metabolic implications of body fat distribution. Diab Care 1991, 14:1132-1143.
6. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 2013, 14:95-109. 10.1111/j.1467-789X.2012.01053.x, 23114091.
7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285. 10.1111/j.1365-2036.2011.04724.x, 21623852.
8. Younossi ZM, Venkatesan C. A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. Panminerva Med 2012, 54:29-37.
9. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009, 24:243-247. 10.1111/j.1440-1746.2008.05740.x, 19215335.
10. Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011, 33:801-814. 10.1111/j.1365-2036.2011.04579.x, 21251033.
11. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004, 59:141-154. 10.1097/01.OGX.0000109523.25076.E2, 14752302.
12. Ciba I, Widhalm K. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. Acta Paediatr 2007, 96:109-112.
13. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013, 28:777-784. 10.1093/humrep/des463, 23315061.
14. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33:981-1030. 10.1210/er.2011-1034, 23065822.
15. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21:27-41. 10.1055/s-2001-12927, 11296694.
16. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. CleveClin J Med 2008, 75:721-728.
17. Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, Chandhoke V, Younossi ZM. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg 2009, 19:617-624. 10.1007/s11695-009-9814-x, 19280268.
18. Baranova A, Randhawa M, Jarrar M, Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn 2007, 7:195-205. 10.1586/14737159.7.2.195, 17331066.
19. Mehta R, Birerdinc A, Hossain N, Afendy A, Chandhoke V, Younossi Z, Baranova A. Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol 2010, 11:39. 10.1186/1471-2199-11-39, 2886049, 20492695.
20. Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 2011, 46:479-484.
21. Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K, Canbay A. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010, 95:343-348. 10.1210/jc.2009-1834, 19906783.
22. Dai R, Yan D, Li J, Chen S, Liu Y, Chen R, Duan C, Wei M, Li H, He T. Activation of PKR/eIF2α signaling cascade is associated with dihydrotestosterone-induced cell cycle arrest and apoptosis in human liver cells. J Cell Biochem 2012, 113:1800-1808.
23. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 1997, 138:3779-3786. 10.1210/en.138.9.3779, 9275065.
24. Bieghs V, Van Gorp PJ, Wouters K, Hendrikx T, Gijbels MJ, van Bilsen M, Bakker J, Binder CJ, Lütjohann D, Staels B, Hofker MH, Shiri-Sverdlov R. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One 2012, 7:e30668. 10.1371/journal.pone.0030668, 3266276, 22295101.
25. Subramanian S, Goodspeed L, Wang S, Kim J, Zeng L, Ioannou GN, Haigh WG, Yeh MM, Kowdley KV, O'Brien KD, Pennathur S, Chait A. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res 2011, 52:1626-1635. 10.1194/jlr.M016246, 3151683, 21690266.
26. Chang W, Goodarzi MO, Williams H, Magoffin DA, Pall M, Azziz R. Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril 2008, 90:2291-2297. 10.1016/j.fertnstert.2007.10.025, 2744855, 18178198.
27. Matsumoto T, Schiller P, Dieterich LC, Bahram F, Iribe Y, Hellman U, Wikner C, Chan G, Claesson-Welsh L, Dimberg A. Ninein is expressed in the cytoplasm of angiogenic tip-cells and regulates tubular morphogenesis of endothelial cells. Arterioscler Thromb Vasc Biol 2008, 28:2123-2130. 10.1161/ATVBAHA.108.169128, 18772498.
28. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, Giordano T, Peale F. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol 2003, 162:1881-1893. 10.1016/S0002-9440(10)64322-2, 1868136, 12759245.
29. Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, Papadimas I, Panidis D. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009, 15:297-307. 10.1093/humupd/dmp006, 19261627.
30. Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol 2012, 373:68-76.
31. Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 2012, 59:1697-1705. 10.1016/j.jacc.2011.11.064, 22554600.
32. Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009, 280:187-193. 10.1007/s00404-008-0884-0, 19107500.
33. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. JClin Endocrinol Metab 2009, 94:3171-3182.
34. Bobbert P, Eisenreich A, Weithäuser A, Schultheiss HP, Rauch U. Leptin and resistin induce increased procoagulability in diabetes mellitus. Cytokine 2011, 56:332-337. 10.1016/j.cyto.2011.05.019, 21733717.
35. Fang WQ, Zhang Q, Peng YB, Chen M, Lin XP, Wu JH, Cai CH, Mei YF, Jin H. Resistin level is positively correlated with thrombotic complications in Southern Chinese metabolic syndrome patients. J Endocrinol Invest 2011, 34:e36-e42.